Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was create
Calithera Terminating Partnership, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Wednesday, 09'th Sep 2020
Calithera signals terminating partnership with Incyte. Lexicon reports dosing in Phase 2 clinical study for LX9211.
Incyte (INCY) Down 2.2% Since Last Earnings Report: Can It Rebound?
11:31am, Thursday, 03'rd Sep 2020
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
WILMINGTON, Del.--(BUSINESS WIRE)--Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Biotech Industry Near-Term Outlook Modest Amid Coronavirus
09:47am, Friday, 28'th Aug 2020
Biotech Industry Near-Term Outlook Modest Amid Coronavirus
CURE® Magazine Seeks Nominations for 2020 MPN Heroes® Recognition Program
12:00am, Tuesday, 25'th Aug 2020
Annual awards program recognizes individuals, institutions and organizations who go above and beyond in their efforts to support patients with MPN.
Amalgamated Bank Has $1.26 Million Position in Incyte Co. (NASDAQ:INCY)
07:38am, Monday, 24'th Aug 2020
Amalgamated Bank reduced its stake in Incyte Co. (NASDAQ:INCY) by 59.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC)
National Comprehensive Cancer Network Adds Monjuvi® (tafasitamab-cxix) to its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Incyte (NASDAQ:INCY) Stock Rating Reaffirmed by Cowen
01:48am, Tuesday, 11'th Aug 2020
Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reissued by stock analysts at Cowen in a report issued on Sunday, AnalystRatings.com reports. Several other brokerages have also weighed in on I
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript
08:46am, Sunday, 09'th Aug 2020
MorphoSys AG (NASDAQ:MOR) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Anja Pomrehn - Head of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Re
The number of confirmed cases of the coronavirus illness COVID-19 climbed above 19 million on Friday, the death toll rose above 715,000 and the U.S. death...
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment
01:11pm, Friday, 07'th Aug 2020
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s undefined...
NIH to test remdesivir with Merck KGaA's interferon therapy as a COVID-19 treatment
01:11pm, Friday, 07'th Aug 2020
The National Institutes of Health said it will conduct a randomized, controlled clinical trial testing a combination of Gilead Sciences Inc.'s remdesivir with Merck KGaA's interferon beta-1a as a tr
Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
12:00am, Thursday, 06'th Aug 2020
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results f
